Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Home » Risk factors for long-COVID in children
A summary of research published in the European Respiratory Journal
Older children and those with allergies could be more at risk of developing long-COVID, according to a new study.
The research, published in the European Respiratory Journal, looked at children who had stayed in hospital with COVID-19 to see how well they recovered and whether a particular group was more likely to develop long-COVID.
518 children admitted to a hospital in Moscow, Russia, between April and August 2020, were included in the study. All children returned home, and their parents completed a survey and a telephone interview about the child’s symptoms in January and February 2021.
Results showed that 126 children, almost 1 in 4, still had symptoms roughly 8 months after they left hospital. The most common symptoms were fatigue (tiredness), disturbed sleep and sensory problems.
The findings suggested that older children (aged 12-18 years) were more likely to experience ongoing symptoms, as well as those children with a history of allergies.
Although a lot of symptoms eased over time, some of the children, almost 1 in 4, were still experiencing problems up to 8 months after they left hospital. 1 in 10 of these children experienced more than one ongoing symptom. The findings are a useful insight into how long-COVID can affect children long-term and can help to inform future work on the topic to understand more about the condition.
Title: Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study
https://erj.ersjournals.com/content/early/2021/06/10/13993003.01341-2021
Sign up to get the latest information and research on lung conditions, hear about our upcoming events and campaigns, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79